Ligand Pharmaceuticals Incorporated (LGND) — Cash Flow Quality Index
Ligand Pharmaceuticals Incorporated (LGND) has a Cash Flow Quality Index of 1.02x as of December 2025. Operating cash flow of $45.84 Million exceeds net income of $44.78 Million, indicating high earnings quality where cash backs reported profits. Explore cash efficiency ratio of Ligand Pharmaceuticals Incorporated to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Ligand Pharmaceuticals Incorporated Cash Flow Quality Index (2007–2025)
Historical Cash Flow Quality Index for Ligand Pharmaceuticals Incorporated across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check LGND cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Ligand Pharmaceuticals Incorporated (2007–2025)
Year-by-year earnings quality comparison for Ligand Pharmaceuticals Incorporated. For live market cap and the full company financial profile, see LGND company net worth.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.40x | $49.36 Million | $124.45 Million | ▼ -58.3% |
| 2023 | 0.95x | $49.58 Million | $52.15 Million | ▼ -31.1% |
| 2021 | 1.38x | $78.80 Million | $57.14 Million | ▲ +3058.3% |
| 2019 | -0.05x | $-29.34 Million | $629.30 Million | ▼ -103.4% |
| 2018 | 1.35x | $194.06 Million | $143.32 Million | ▼ -81.8% |
| 2017 | 7.45x | $93.57 Million | $12.56 Million | ▲ +4452.7% |
| 2015 | 0.16x | $41.73 Million | $254.93 Million | ▼ -91.3% |
| 2014 | 1.89x | $20.57 Million | $10.89 Million | ▼ -19.4% |
| 2013 | 2.34x | $20.69 Million | $8.83 Million | ▲ +2133.4% |
| 2011 | -0.12x | $-1.17 Million | $10.17 Million | ▲ +66.8% |
| 2007 | -0.35x | $-97.73 Million | $281.69 Million | — |